Tallahassee, Fla. (Feb. 14, 2019) Synth Taxus, LLC is pleased to announce the successful completion of our first kilogram scale production run. This milestone in our manufacturing strategy for synthetic taxane anticancer Active Pharmaceutical Ingredients (APIs) is based on Professor Robert Holton’s beta-lactam technology at Florida State University. With continuing innovation for this superior technology at Synth Taxus, we now can offer taxane APIs with highest quality taxane APIs with world leading efficiency.
“With the improved beta-lactam technology, we are producing our leading anticancer APIs products like cabazitaxel and docetaxel in excess of 99.5% purity and No Single Impurity (NSP) greater than 0.10%. We are eager to proceed to the next step to produce these APIs under current Good Manufacturing Practice (cGMP) and Drug Master File (DMF) registrations” said Dr. Phong Vu, PhD, Synth Taxus Founder.